Characteristics of the cohort of patients presenting a with NMOS
| Characteristics | NMOS (n=51) | NMO (n=28) | Limited form of NMO (n=23) |
|---|---|---|---|
| Gender: female (%) | 90.2 | 92.8 | 87 |
| Age at treatment, years (SD) | 41.7 (12.2) | 39.7 (12.9) | 44.1 (11.2) |
| Other autoimmune disease (%) | 21.6 | 25 | 19 |
| ON during 1st relapse (%) | 49 | 64.3 | 33.3 |
| Disease duration, years (SD) | 4 (5.4) | 6.5 (6.1) | 0.9 (1.3) |
| Number of relapses before treatment | 3.9 | 5.2 | 1.8 |
| ARR year before treatment | 1.8 | 1.9 | 1.4 |
| EDSS at treatment (SD) | 5.8 (1.9) | 5.9 (1.8) | 5.7 (2) |
| Increase in EDSS year before treatment | 3.7 (2.5) | 2.6 (2.2) | 5 (2.5) |
| IgG-NMO seropositivity (%) | 50 | 50 | 50 |
| MTX cumulative dose, mg (SD) | 107 (28) | 111 (23) | 101 (32) |
| Time after treatment, years (SD) | 4.8 (3.1) | 5.7 (3.3) | 3.9 (2.7) |
ARR, annualised relapse rate; EDSS, expanded disability status scale; IgG, immunoglobulin G; MTX, mitoxantrone; NMO, neuromyelitis optica; NMOS, neuromyelitis optica spectrum; ON, optic neuritis.